Latecomer JAKi ‘Rinvoq’ now has the most indications

By | translator Alice Kang

21.10.06 18:24:32

가나다라 0

Adds psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis indication … becomes the JAK inhibitor with the most indications

Xeljanz and Olumiant currently leads the market… Will Rinvoq, which occupies 1/10 of the market, change the landscape?

Safety concern over severe heart disease remains… the whole market may retract due to safety issue

The latecomer JAK inhibitor, Abbvie’s ‘Rinvoq,’ is seeking to overturn the market landscape by greatly expanding its indications. Whether the drug can break the two-way lead battle between Xeljanz and Olumiant, is gaining attention.

According to the Ministry of Food and Drug Safety, Abbvie’s ‘Rinvoq (upadacitinib)’ received additional approval for psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis indications. With the original rheumatoid arthritis indication, Abbvie’s drug is now approved for 4 indications in total.

More specifically, Rinvoq is indicated for the treatment of adults and patients over the age of 12 with moderate to severe atopic dermatitis. In ankyl

(same@dailypharm.com)

If you want to see the full article, please JOIN US (click)